Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from RedHill Biopharma ( (RDHL) ) is now available.
On November 26, 2025, RedHill Biopharma Ltd. announced an increase in the maximum aggregate offering amount of its American Depositary Shares under an At The Market Offering Agreement with H.C. Wainwright & Co., LLC. This strategic move is expected to enhance the company’s financial flexibility and support its ongoing operations and growth initiatives in the competitive biopharmaceutical industry.
The most recent analyst rating on (RDHL) stock is a Sell with a $1.00 price target. To see the full list of analyst forecasts on RedHill Biopharma stock, see the RDHL Stock Forecast page.
Spark’s Take on RDHL Stock
According to Spark, TipRanks’ AI Analyst, RDHL is a Underperform.
The overall stock score is heavily influenced by RedHill Biopharma’s challenging financial performance, characterized by consistent losses and high leverage. Technical analysis further indicates bearish momentum, while the lack of valuation metrics underscores financial instability.
To see Spark’s full report on RDHL stock, click here.
More about RedHill Biopharma
RedHill Biopharma Ltd. is a biopharmaceutical company based in Tel Aviv, Israel. It focuses on the development and commercialization of proprietary drugs for the treatment of gastrointestinal diseases and cancer.
Average Trading Volume: 1,820,652
Technical Sentiment Signal: Sell
Current Market Cap: $3.7M
Find detailed analytics on RDHL stock on TipRanks’ Stock Analysis page.